Raffi F - Search Results

1

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group. Lê MP, et al. Among authors: raffi f. J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193. J Antimicrob Chemother. 2018. PMID: 29905808 Clinical Trial.

2

Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, Vilde JL. Leport C, et al. Among authors: raffi f. Am J Med. 1988 Jan;84(1):94-100. doi: 10.1016/0002-9343(88)90014-9. Am J Med. 1988. PMID: 3337134

3

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.

Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C; Aproco Study Group. Le Moing V, et al. Among authors: raffi f. AIDS. 2002 Jan 4;16(1):21-9. doi: 10.1097/00002030-200201040-00004. AIDS. 2002. PMID: 11741159 Clinical Trial.

4

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

Chêne G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, May T, Journot V, Raffi F, Jarrousse B, Grappin M, Lepeu G, Molina JM. Chêne G, et al. Among authors: raffi f. Clin Infect Dis. 2002 Mar 1;34(5):649-57. doi: 10.1086/338811. Epub 2002 Jan 24. Clin Infect Dis. 2002. PMID: 11810598 Clinical Trial.

5

Final analysis of the Trilège induction-maintenance trial: results at 18 months.

Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Hazebrouck S, Pialoux G, Aboulker JP, Brun Vezinet F. Flandre P, et al. Among authors: raffi f. AIDS. 2002 Mar 8;16(4):561-8. doi: 10.1097/00002030-200203080-00007. AIDS. 2002. PMID: 11872999 Clinical Trial.

6

Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.

Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi F; Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Flandre P, et al. Among authors: raffi f. Antivir Ther. 2002 Jun;7(2):113-21. Antivir Ther. 2002. PMID: 12212923 Clinical Trial.

7

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R, Besnier JM, Chêne G, Raffi F, Brun-Vézinet F; APROCO Study Group. Masquelier B, et al. Among authors: raffi f. J Infect Dis. 2002 Nov 15;186(10):1503-7. doi: 10.1086/344358. Epub 2002 Oct 23. J Infect Dis. 2002. PMID: 12404170

8

The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination.

Duran S, Peytavin G, Carrieri P, Raffi F, Ecobichon JL, Pereira E, Cassuto GP, Spire B, Leport C; Antiprotease Cohort (APROCO) study group. Duran S, et al. Among authors: raffi f. AIDS. 2003 May 2;17(7):1096-9. doi: 10.1097/00002030-200305020-00025. AIDS. 2003. PMID: 12700466

9

R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.

Masquelier B, Droz C, Dary M, Perronne C, Ferré V, Spire B, Descamps D, Raffi F, Brun-Vézinet F, Chêne G; APROCO/COPILOTE Study Group. Masquelier B, et al. Among authors: raffi f. Antimicrob Agents Chemother. 2003 Nov;47(11):3623-6. doi: 10.1128/AAC.47.11.3623-3626.2003. Antimicrob Agents Chemother. 2003. PMID: 14576131 Free PMC article. Clinical Trial.

10

Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.

Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group. Le Moing V, et al. Among authors: raffi f. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9. doi: 10.1097/00126334-200312150-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14657760

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

723 results

Search Page

Filters